See more : Emami Limited (EMAMILTD.NS) Income Statement Analysis – Financial Results
Complete financial analysis of RegeneRx Biopharmaceuticals, Inc. (RGRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RegeneRx Biopharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Global Capital Partners Inc. (GCPL) Income Statement Analysis – Financial Results
- National Metal Manufacturing and Casting Co. (2220.SR) Income Statement Analysis – Financial Results
- On Real International Holdings Limited (8245.HK) Income Statement Analysis – Financial Results
- Advantage Risk Management Co., Ltd. (8769.T) Income Statement Analysis – Financial Results
- ZEAL Network SE (TIMA.DE) Income Statement Analysis – Financial Results
RegeneRx Biopharmaceuticals, Inc. (RGRX)
About RegeneRx Biopharmaceuticals, Inc.
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 76.76K | 76.76K | 76.76K | 76.76K | 69.67K | 56.65K | 93.31K | 60.61K | 0.00 | 29.48K | 1.34M | 1.51M | 849.54K | 0.00 | 168.41K | 240.32K | 272.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.27K | 215.03K | 542.24K | 105.59K |
| Cost of Revenue | 0.00 | 6.64 | 4.92 | 65.11 | 81.04 | 3.05K | 237.34 | 203.19 | 367.28 | 188.64 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 76.76K | 76.75K | 76.76K | 76.70K | 69.59K | 53.60K | 93.07K | 60.41K | -367.28 | 29.30K | 1.34M | 1.51M | 849.54K | 0.00 | 168.41K | 240.32K | 272.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.27K | 215.03K | 542.24K | 105.59K |
| Gross Profit Ratio | 100.00% | 99.99% | 99.99% | 99.92% | 99.88% | 94.62% | 99.75% | 99.66% | 0.00% | 99.36% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 6.64K | 4.92K | 65.11K | 81.04K | 143.91K | 237.34K | 203.19K | 367.28K | 188.64K | 1.16M | 5.07M | 2.71M | 3.72M | 7.11M | 8.89M | 6.40M | 4.03M | 2.18M | 775.75K | 885.63K | 139.12K | 64.80K | 1.28K | 41.34K | 85.70K | 1.05M | 2.75M |
| General & Administrative | 1.42M | 1.40M | 1.37M | 1.27M | 1.31M | 1.36M | 1.53M | 1.57M | 1.19M | 755.09K | 1.02M | 2.46M | 3.17M | 2.78M | 3.85M | 3.20M | 2.67M | 1.64M | 1.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 59.69K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.48M | 1.40M | 1.37M | 1.27M | 1.31M | 1.36M | 1.53M | 1.57M | 1.19M | 755.09K | 1.02M | 2.46M | 3.17M | 2.78M | 3.85M | 3.20M | 2.67M | 1.64M | 1.16M | 848.74K | 559.64K | 356.58K | 398.64K | 200.89K | 551.75K | 784.32K | 968.57K | 2.06M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -582.90K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.48M | 1.41M | 1.37M | 1.34M | 1.39M | 1.50M | 1.77M | 1.77M | 1.56M | 943.74K | 2.18M | 7.52M | 5.88M | 6.51M | 10.96M | 12.08M | 9.06M | 5.67M | 3.34M | 1.62M | 1.45M | 495.70K | 463.43K | 202.17K | 593.09K | 870.01K | 2.02M | 4.81M |
| Cost & Expenses | 1.48M | 1.41M | 1.37M | 1.34M | 1.39M | 1.50M | 1.77M | 1.77M | 1.56M | 943.74K | 2.18M | 7.52M | 5.88M | 6.51M | 10.96M | 12.08M | 9.06M | 5.67M | 3.34M | 1.62M | 1.45M | 495.70K | 463.43K | 202.17K | 593.09K | 870.01K | 2.02M | 4.81M |
| Interest Income | 183.00 | 234.00 | 3.81K | 11.04K | 0.00 | 0.00 | 0.00 | 101.00 | 153.00 | 16.00 | 26.00 | 4.49K | 8.19K | 12.44K | 149.78K | 666.46K | 522.70K | 214.68K | 16.44K | 7.57K | 30.08K | 30.03K | 18.70K | 0.00 | 4.88K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 325.65K | 324.88K | 232.63K | 153.41K | 87.28K | 170.88K | 173.36K | 172.88K | 183.47K | 100.94K | 5.70K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 70.00 | 42.95K | 0.00 | 0.00 | 0.00 | 0.00 | 14.52K | 0.00 | 132.07K | 0.00 |
| Depreciation & Amortization | 183.00 | 1.33M | 1.42K | 27.22K | 2.75K | 3.05K | 3.33K | 3.40K | 4.82K | 5.00K | 7.57K | 9.08K | 9.74K | 16.55K | 19.40K | 21.20K | 18.11K | 15.63K | 4.18K | 4.10K | 3.29K | 1.23K | 731.00 | 305.00 | 1.30K | 5.04K | 77.19K | 306.63K |
| EBITDA | -1.40M | -1.27M | -1.29M | -1.25M | -1.90M | -1.44M | -1.67M | -5.09M | -1.55M | -565.40K | -833.73K | -6.00M | -5.02M | -6.48M | -10.79M | -11.16M | -8.25M | -5.44M | -3.32M | -1.62M | -1.45M | -691.25K | -1.17M | 291.30K | -588.52K | -649.94K | -1.40M | -4.40M |
| EBITDA Ratio | -1,826.20% | -1,730.41% | -1,681.50% | -1,627.65% | -2,732.31% | -2,544.63% | -1,790.51% | -2,814.68% | 0.00% | -3,083.83% | -62.09% | -397.10% | -591.19% | 0.00% | -6,393.46% | -4,919.78% | -3,219.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -70,192.86% | -302.67% | -253.80% | -4,308.75% |
| Operating Income | -1.40M | -1.33M | -1.29M | -1.26M | -1.32M | -1.44M | -1.67M | -1.71M | -1.56M | -914.25K | -841.33K | -6.01M | -5.03M | -6.51M | -10.79M | -11.84M | -8.79M | -5.67M | -3.34M | -1.62M | -1.45M | -495.70K | -463.43K | -202.17K | -589.83K | -654.98K | -1.48M | -4.71M |
| Operating Income Ratio | -1,826.44% | -1,730.71% | -1,686.46% | -1,643.89% | -1,899.56% | -2,550.01% | -1,794.08% | -2,820.46% | 0.00% | -3,100.84% | -62.65% | -397.70% | -592.33% | 0.00% | -6,404.97% | -4,928.60% | -3,225.68% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -18,065.08% | -304.59% | -272.70% | -4,457.81% |
| Total Other Income/Expenses | -325.46K | -269.24K | -228.83K | -142.37K | -670.18K | 1.83M | 1.90M | -3.56M | -1.20M | 242.91K | -5.67K | 4.49K | 8.19K | 12.44K | 149.78K | 11.84M | 522.71K | 214.68K | 16.37K | 0.00 | 10.65K | 196.78K | 704.39K | -493.16K | 589.83K | 911.00 | -25.28K | 149.25K |
| Income Before Tax | -1.73M | -1.60M | -1.52M | -1.40M | -1.99M | 385.09K | 229.13K | -5.27M | -2.75M | -671.34K | -847.00K | 0.00 | 0.00 | 0.00 | -11.18M | -11.18B | 0.00 | 0.00 | 0.00 | 0.00 | -1.43M | -298.92K | 240.96K | -695.33K | 1.11M | -654.07K | -1.50M | -4.56M |
| Income Before Tax Ratio | -2,250.43% | -2,081.47% | -1,984.56% | -1,829.35% | -2,861.55% | 679.75% | 245.56% | -8,695.44% | 0.00% | -2,276.97% | -63.08% | 0.00% | 0.00% | 0.00% | -6,637.39% | -4,651,286.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 34,102.63% | -304.17% | -277.36% | -4,316.47% |
| Income Tax Expense | 0.00 | 324.64K | 228.83K | 153.41K | -582.90K | 98.61K | 173.36K | 172.88K | 183.47K | 100.94K | 26.00 | -4.49K | -8.19K | -12.44K | -541.19K | 665.79M | -522.70K | -214.68K | -16.37K | 35.38K | -40.73K | -345.09K | -1.50M | 509.07K | -2.35M | 140.45K | 157.35K | -614.85K |
| Net Income | -1.73M | -1.92M | -1.75M | -1.56M | -1.99M | 286.49K | 229.13K | -5.27M | -2.75M | -671.34K | -847.00K | -6.01M | -5.02M | -6.49M | -10.64M | -11.18M | -8.27M | -5.45M | -3.33M | -1.66M | -1.40M | -150.61K | 1.04M | -711.23K | 1.76M | -795.43K | -1.64M | -4.09M |
| Net Income Ratio | -2,250.43% | -2,504.40% | -2,282.66% | -2,029.20% | -2,861.55% | 505.70% | 245.56% | -8,695.44% | 0.00% | -2,276.97% | -63.08% | -397.40% | -591.37% | 0.00% | -6,316.04% | -4,651.29% | -3,033.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 53,953.08% | -369.91% | -301.71% | -3,875.52% |
| EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | 0.00 | 0.00 | -0.05 | -0.03 | -0.01 | -0.01 | -0.08 | -0.07 | -0.12 | -0.21 | -0.24 | -0.21 | -0.15 | -0.10 | -0.06 | -0.06 | -0.01 | 0.06 | -0.06 | 0.15 | -0.07 | -0.18 | -0.46 |
| EPS Diluted | -1.20 | -0.01 | -0.01 | -0.01 | -0.02 | 0.00 | 0.00 | -0.05 | -0.03 | -0.01 | -0.01 | -0.08 | -0.07 | -0.12 | -0.21 | -0.24 | -0.21 | -0.15 | -0.10 | -0.06 | -0.06 | -0.01 | 0.05 | -0.06 | 0.15 | -0.07 | -0.18 | -0.46 |
| Weighted Avg Shares Out | 143.55M | 138.59M | 133.36M | 130.97M | 120.72M | 107.44M | 106.79M | 101.53M | 93.19M | 81.73M | 81.63M | 80.14M | 68.44M | 55.68M | 50.97M | 46.47M | 40.12M | 36.84M | 32.91M | 28.52M | 25.56M | 19.48M | 18.85M | 11.98M | 11.74M | 11.36M | 9.09M | 8.98M |
| Weighted Avg Shares Out (Dil) | 1.44M | 138.59M | 133.36M | 130.97M | 120.72M | 120.93M | 125.92M | 101.53M | 93.19M | 81.73M | 81.63M | 80.14M | 68.44M | 55.68M | 50.97M | 46.47M | 40.12M | 36.84M | 32.91M | 28.52M | 25.56M | 19.48M | 20.83M | 11.98M | 11.74M | 11.36M | 9.09M | 8.98M |
RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations
ROCKVILLE, Md. , Aug. 15, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, announced that it has today effected a 1-for-100 reverse split in the...
RegeneRx Receives Stockholder Approval for Reverse Stock Split
ROCKVILLE, Md. , Aug. 7, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, announced that, pursuant to the company's consent solicitation dated July 11, 2023,...
RegeneRx To Extend Consent Solicitation Vote
ROCKVILLE, Md. , Aug. 1, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, announced that, pursuant to the company's consent solicitation dated July 11, 2023,...
Researchers Identify Thymosin Beta 4's Potential Role in Treatment of Acute Kidney Injury and the Reduction of Mortality in Patients with Sepsis
ROCKVILLE, Md., Oct. 6, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that a new independent research paper was published identifying Thymosin Beta 4's (Tβ4) potential in...
RegeneRx Issues Letter To Stockholders
ROCKVILLE, Md., July 22, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, has issued a Letter to Stockholders updating its recent financing, the FDA regulatory...
RegeneRx JV Updates RGN-259 Regulatory Progress for Dry Eye Syndrome
ROCKVILLE, Md., July 14, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has released an update from its U.S. joint venture, ReGenTree LLC, regarding its progress and prospects...
RegeneRx Biopharmaceuticals, Inc. Closes $2 Million Private Placement
ROCKVILLE, Md., July 1, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that it closed its previously announced private placement offering of common stock and warrants for...
RegeneRx Biopharmaceuticals, Inc. Announces $2 Million Private Placement
ROCKVILLE, Md., June 28, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration), today announced that it has entered into a definitive agreement with certain institutional and accredited investors, including...
RegeneRx Joint Venture Reports Positive Results from ARISE-3 Clinical Trial Using RGN-259 to Treat Dry Eye Syndrome
ROCKVILLE, Md., May 14, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted a press release from its U.S. joint venture, ReGenTree LLC, on its website pursuant...
RegeneRx Reports Topline Results of ARISE-3 Dry Eye Trial
ROCKVILLE, Md., March 18, 2021 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage biopharmaceutical company focused on tissue protection, repair and regeneration, announced that the ARISE-3 Phase 3 clinical trial evaluating RGN-259 eyedrops for the treatment of...
Source: https://incomestatements.info
Category: Stock Reports